Diagnostics

Qualio announces Compliance Intelligence, the AI-powered solution advancing its industry-leading Life Sciences GRC platform

AI-powered gap analysis, continuous compliance monitoring, real-time visibility, and pre-built life sciences frameworks help organizations reduce audit preparation from months...

MD INTEGRATIONS RAISES $77 MILLION FROM UPDATA PARTNERS AND DENALI GROWTH PARTNERS TO ACCELERATE INNOVATION IN TELEHEALTH; APPOINTS PRESIDENT & COO

With triple-digit year-over-year growth and millions of consults delivered, MDI expands its doctor-only platform and leadership team to define the future...

Medical Care Technologies Inc. (OTC PINK:MDCE) Accelerates Growth Trajectory as Its Diverse AI Ecosystem Eyes $450 Billion in Multi-Market Potential

MESA, ARIZONA / ACCESS Newswire / October 14, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced that its...

Zomedica Expands Grovet’s Distribution Agreement to Include Zomedica’s Diagnostic and Therapeutic Device Products Across the European Union

Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in...

Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by Advancements in Targeted Therapies and Drug Delivery Innovations | According DataM Intelligence

AUSTIN, Texas and TOKYO, Oct. 13, 2025 /PRNewswire/ -- The global nanomedicine market size reached US$ 169.51 Billion in 2024...

University of Michigan study presentation at ANESTHESIOLOGY 2025 supports clinical and environmental benefits of End-tidal Control

The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan...

University of Michigan study presentation at ANESTHESIOLOGY 2025 supports clinical and environmental benefits of End-tidal Control

The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan...

HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam

error: Content is protected !!